Sir,
The treatment of juxtapapillary retinal capillary haemangioma (RCH) raises difficulties because of the vicinity to the optic nerve. As juxtapapillary RCHs are frequently located at the temporal site of the disk,1, 2 chronic leakage often threatens the macula.3 Photodynamic therapy (PDT) with verteporfin has shown to succeed in shrinking RCH, but repeated treatment often resulted in poor functional results.2, 3 We report on a case of juxtapapillary RCH, successfully treated with a combination of intravitreal bevacizumab and PDT.
Case report
A 58-year-old patient complained about diminished vision since 2 days. Visual acuity (VA) was RE: 20/200 and LE: 20/25. Ophthalmoscopy revealed an elevated mass overlying the temporal half of the optic nerve with invasion of the peripapillary area and macular exudation (Figure 1). Fluorescence angiography showed early hyperfluorescence of the tumour vessels. Perimetry revealed a centrocoecal scotoma. Systemic staging was unremarkable.1
Informed consent was obtained in accordance with IRB approval. Two days after the intravitreal injection of 1.25 mg bevacizumab, a decrease in exudation was seen. VA increased to 20/40. Two weeks later, PDT (verteporfin 6 mg/m2 over 10 min) was performed with an irradiation time of 166 s. Four weeks after the PDT, the tumour showed marked regression and an increase in VA to 20/25. Perimetry also revealed regression of the scotoma to a small inferotemporal spot. One year after the therapy, the macula remained dry and VA was 20/25 (Figure 2).
Comment
The case presented underlines that bevacizumab treatment alone can cause a reduction of the tumour-associated exudation, presumably by depleting endothelial fenestrae and altering intercellular adhesion molecules.4 Vascular complications and phototoxicity are most likely the reasons for the vision loss after PDT in juxtapapillary RCH.2 The anti-exudative effect of bevacizumab promises better delineation of the juxtapapillary RCH and consequently allows more precisely adjustment of the PDT irradiation to minimize the collateral damage. The single combination therapy of bevacizumab and PDT had a longlasting effect and thus eliminated the necessity of further destruction by repeated PDT.5 Long-term follow-up of other cases is necessary to make a conclusive statement about the combination therapy of juxtapapillary RCH.
References
Webster AR, Maher ER, Moore AT . Clinical characteristics of ocular angiomatosis in von Hippel–Lindau disease and correlation with germline mutation. Arch Ophthalmol 1999; 117: 371–378.
Schmidt-Erfurth UM, Kusserwo C, Barbazetto IA, Laqua H . Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology 2002; 109: 1256–1266.
McCabe CM, Flynn HW, Shields CL, Shields JA, Regillo CD, McDonald HR et al. Juxtapapillary capillary hemangiomas: clinical features and visual acuity outcomes. Ophthalmology 2000; 107: 2240–2248.
Wang W, Dentler WL, Borchardt RT . VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol 2001; 280: H434–H440.
Bakri SJ, Sears JE, Singh AD . Transient closure of retinal capillary hemangioma with verteporfin photodynamic therapy. Retina 2005; 25: 1103–1104.
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of interest: None
Rights and permissions
About this article
Cite this article
Ziemssen, F., Voelker, M., Inhoffen, W. et al. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye 21, 1125–1126 (2007). https://doi.org/10.1038/sj.eye.6702896
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.eye.6702896